Home » Multimedia » Podcasts » BioWorld Insider Podcast » A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
BioWorld Insider Podcast
One-on-one with medical innovators
Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us each week for a new conversation.
About a third of all human cancers are driven by mutations in RAS genes. Many RAS mutations make cells resistant to a lot of approved cancer therapies. Some members of the RAS gene family encode proteins that have a key role in cell signaling. When those genes are mutated, cells grow uncontrollably and evade death signals. So far, blocking RAS gene function has not worked. Despite that, there’s a highly competitive drug development landscape.
Though Revolution Medicines Inc.’s RAS companion/SHP2 inhibitor RMC-4630 failed to show efficacy in two early stage combination trials, the company is moving forward with the candidate, its lead asset, partnered with Sanofi SA as part of a potential $550 million deal.
Mark Goldsmith, Revolution’s president, CEO and chairman joined the BioWorld Insider Podcast to discuss the challenges and progress in other experiments.
As James Peyer, the CEO of Cambrian Biopharma Inc., watched his grandfather fail every cancer treatment and pass away, he also saw the structure of his future company being born. Waiting until people became sick was the wrong way to treat disease, he found. Instead, Cambrian was created to develop anti-aging therapies, a unique business model that fits the new field of geroscience. To do that, Cambrian became a biotech business, a VC fund and an incubator. Peyer spoke to the BioWorld Insider Podcast about his pipeline and how he goes about fundraising in a little understood field.
After many years of research and development, drug-induced weight loss has matured into a viable therapeutic option. But do the drugs directly help people become healthier or is it the weight loss? There are longstanding concerns that the health effects of weight might be overrated. And new studies show fitness improves health outside of weight. So, can a person still be considered healthy despite being over a “normal” weight? How will future medical science consider what is called the obesity epidemic? In this edition of the BioWorld Insider podcast, BioWorld Science Managing Editor Anette Breindl, discusses her new analysis of multiple studies related to weight loss, metabolic health and fitness which in many ways goes against the mainstream health care state of mind about obesity.
We wrapped up 2022 and are preparing for 2023 on this BioWorld Insider podcast. Staff writer Lee Landenberger talked to four CEOs, visionaries of companies producing new science and drug development. The CEOs offered their insights into what happened this year and looked at the challenges and opportunities for next year.
Karen Zaderej, CEO of Axogen Inc., detailed a successful phase III study of its peripheral nerve repair product, Advance Nerve Graft, despite staffing challenges at hospitals.
Sean Bohen, CEO of Olema Oncology Inc., whose company is developing therapies to treat women's cancers, reflected on how Olema overcame financing challenges.
Rob Ross, the CEO of Surface Oncology Inc., spoke about how equity funding has dried up and has forced Surface to be creative in order to keep moving forward with its antibody against IL-27 to treat non-small-cell lung cancer.
Rob Etherington, the CEO of Clene Nanomedicine Inc., revealed how his company will be leaning into strategic M&A and licensing opportunities to keep its multiple sclerosis candidate, which can improve function on top of standard-of-care MS drugs, moving forward.
An analyst recently observed that mental health treatments are stuck where cancer was 50 years ago. However, there have been major advancements in developing psychedelic medicines to address that problem. BioWorld staff writer Lee Landenberger talked with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders. Lanthier discussed challenges facing companies developing psychedelic treatments and how to overcome the one-size-fits-all, trial-and-error approach to mental health treatment that often seems stuck in the past.
BioWorld writers bring you the details of new R&D alliances, financings, IPOs and M&A every day. These stories are the heartbeat of the relationships between industry giants and their smaller, more innovative peers. But what's the top-line read for dealmaking these days? With nearly 1,000 biopharma deals completed through early August amid a volatile economic climate, there's a lot to talk about. Join the BioWorld Insider podcast as we talk with Senior Analyst Karen Carey, whose data-driven research delivers a detailed picture of the ups and downs. For starters, the sector has seen sharp declines this year in stocks and less money being raised. “What we are seeing seems to be a correction of the intense enthusiasm – the zeal for biopharma during 2020 and 2021 when nobody knew what was going on with COVID,” Carey said.
In Extending the human lifespan, a BioWorld special report, the team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing potential “Fountain of Youth” candidate drugs. In this episode of the BioWorld Insider Podcast, the team discussed the report’s highlights and key takeaways. In what could be a holy grail for humanity, anti-aging drugs would simultaneously reduce the risk of multiple age-related illnesses in one. BioWorld found that investments in life-extending drugs and the number of clinical trials are on the rise. Can we hopscotch over the many diseases of aging? The impact could be staggering. Equitable access to drugs and therapies tackling aging could reduce health care costs in a major way and improve quality of life.